Clinical Trials in Degenerative Diseases : Table of Contents

Users Online: 89

Article Cited by others

RESEARCH ARTICLE

Wharton’s jelly derived allogeneic mesenchymal stromal cells for treatment of type 1 diabetes: Study protocol for a double-blinded, randomized, parallel, placebo-controlled trial

Carlsson Per-Ola, Svahn Mathias G

Year : 2018| Volume: 3| Issue : 2 | Page no: 32-37

This article has been cited by

1	Electromagnetic field exposure as a plausible approach to enhance the proliferation and differentiation of mesenchymal stem cells in clinically relevant scenarios

	Haslinda Abdul Hamid, Vahid Hosseinpour Sarmadi, Vivek Prasad, Rajesh Ramasamy, Azizi Miskon

	Journal of Zhejiang University-SCIENCE B. 2022; 23(1): 42

	[Pubmed] [Google Scholar] [DOI]

2	Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era

	Ammira Al-Shabeeb Akil,Esraa Yassin,Aljazi Al-Maraghi,Elbay Aliyev,Khulod Al-Malki,Khalid A. Fakhro

	Journal of Translational Medicine. 2021; 19(1)

	[Pubmed] [Google Scholar] [DOI]

3	Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges

	Mohamed M. Kamal,Dina H. Kassem

	Frontiers in Cell and Developmental Biology. 2020; 8

	[Pubmed] [Google Scholar] [DOI]

4	Wharton’s Jelly MSCs: Potential Weapon to Sharpen for Our Battle against DM

	Dina H. Kassem,Mohamed M. Kamal

	Trends in Endocrinology & Metabolism. 2020;

	[Pubmed] [Google Scholar] [DOI]

5	Strategy for the Generation of Engineered Bone Constructs Based on Umbilical Cord Mesenchymal Stromal Cells Expanded with Human Platelet Lysate

	Ingrid Silva-Cote,Mónica Cruz-Barrera,Mariana Cañas-Arboleda,Luz Correa-Araujo,Leidi Méndez,Joanna Jagielska,Bernardo Camacho,Gustavo Salguero

	Stem Cells International. 2019; 2019: 1

	[Pubmed] [Google Scholar] [DOI]